Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura M Chambers

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Gynecologic Oncology|July 7, 2020
A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncologyLaura M Chambers, Anthony B Costales, Katie Crean-Tate, et al.
Gynecologic Oncology|August 30, 2025
The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapyMolly Morton, Julia Chalif, Jessica Sciuva, et al.
Gynecologic Oncology|July 10, 2026
Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?Paulina J Haight, Julia C Sakach, Laura M Chambers, et al.
Gynecologic Oncology|June 4, 2021
Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapyLaura M Chambers, Julia Chalif, Meng Yao, et al.
Gynecologic Oncology|August 28, 2023
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?Molly Morton, Eric M McLaughlin, Corinne A Calo, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancerCourtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|March 29, 2026
Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility studyJulia Chalif, Catherine Moruzzi, Jessica Velasquez, et al.
Gynecologic Oncology|June 1, 2025
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapyQuinn Kistenfeger, Paulina J Haight, Monica Levine, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Gynecologic Oncology|July 7, 2020
A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncologyLaura M Chambers, Anthony B Costales, Katie Crean-Tate, et al.
Gynecologic Oncology|August 30, 2025
The price of delay: Insurance-related treatment delays in patients with gynecologic cancer receiving immunotherapyMolly Morton, Julia Chalif, Jessica Sciuva, et al.
Gynecologic Oncology|July 10, 2026
Response to mirvetuximab soravtansine and weekly paclitaxel based on treatment sequencing in platinum-resistant ovarian cancer: Does order matter?Paulina J Haight, Julia C Sakach, Laura M Chambers, et al.
Gynecologic Oncology|June 4, 2021
Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapyLaura M Chambers, Julia Chalif, Meng Yao, et al.
Gynecologic Oncology|August 28, 2023
Prevalence of type 2 diabetes diagnoses in the perioperative and survivorship periods following surgical management of endometrial cancer: An opportunity for screening and intervention?Molly Morton, Eric M McLaughlin, Corinne A Calo, et al.
Gynecologic Oncology|April 3, 2026
Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancerJulia Chalif, Molly Morton, Anna Gonzalez, et al.
Gynecologic Oncology|June 5, 2024
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84]Courtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|March 30, 2024
RETRACTED: Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancerCourtney J Riedinger, David A Barrington, Christa I Nagel, et al.
Gynecologic Oncology|March 29, 2026
Implementing non-invasive biospecimen collection in gynecologic oncology: Insights from a prospective gut microbiome feasibility studyJulia Chalif, Catherine Moruzzi, Jessica Velasquez, et al.
Gynecologic Oncology|June 1, 2025
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapyQuinn Kistenfeger, Paulina J Haight, Monica Levine, et al.
Pageof 8